Co-Founders Luke Evnin and Steven St. Peter describe the idea behind the firm, the value in partnering with philanthropies who know these diseases best, and why I&I is going through such a revolution currently.

Founder and CEO Bent Jakobsen describes the science behind the platform, which he believes is unique in that it is delivered systemically, but is designed to bypass healthy tissue and only target tumor cells (without the need for screening). It targets the integrin αvβ6.

Interviewed by Sisterhood editorial board member Grace Colón, Dr. Gujrathi discusses a three pillar framework for success she has learned during her career in life sciences: know thyself, understand your environment, and set yourself up for success. Interview Chapters: Sheila’s background - 0:34 | Framework of success - 6:21 | Getting everyone involved - 16:51 | Not sacrificing the good for the perfect - 19:37 | A culture of accepting feedback - 23:03 | Compassion - 28:2

He describes his early life and education, 18 years of company building at Flagship Pioneering, founding Averin (previously called Bedford Bridge) with his brother, and investing at the intersection of healthcare and technology. Chapters Background & Early Life - 0:23 Education & MD PhD - 5:49 Bob Langer - 11:48 Flagship - 14:18 Microbiome - 25:01 The institutionalization of company creation - 34:41 Deploying Capital - 42:22 Averin - 50:39 Biosensor Company - 59:01 Consumeriz

CEO Iain Foulkes describes the impact Cancer Research Horizons has already made (14 marketed medicines), which has allowed more than £600M in royalty income to be reinvested in research. He describes the structure of the organization, a new startup fund, and some notable investments.

He describes getting through the last few years and how he thinks about 2026. Plus, comments on Xenon, Madrigal, and Alkermes. Brought to you by

He discusses the rationale behind the firm's asset-centric approach and highlights Vicebio as an example of how it works. Plus, his take on the current investment environment. Coverage brought to you by

Sean Bohen explains what he believes is the significance of the Roche announcement, and why he believes Olema's could potentially be a best in class oral SERD. Plus, a preview of data that will deliver sometime next year. Coverage brought to you by

He discusses Zealand's partnership with Roche, and new data that will be coming next year. Plus, the company's partnership with Boehringer on survodutide. Coverage brought to you by

CEO Laurent Levy introduces us to the company's Curadigm Nanoprimer platform and explains its potential use cases. Plus, an update on the company's JNJ partnership, and a recent royalty deal. Coverage brought to you by

He shares his take on the capacity for pharma to do more buying, and list his favorite areas of science, which include I&I, CNS/Neurology, and modalities such as bi-specifics and tri-specifics. Coverage brought to you by

He mentions momelotinib, Blenrep, B7-H3, depemokimab, efimosfermin, IL-33, TSLP, and more. Plus, GSK's dealmaking strategy. Coverage brought to you by

CEO Kenneth Galbraith explains the new dual business focus and walks us through the topline HER2 data. Coverage brought to you by

He covers the company's oral IL-23 (partnered with JNJ), rusfertide (partnered with Takeda), and a new early stage obesity program. Coverage brought to you by

Alexandra Pygall, Naomi Leach, Kristian Shearsby, and James Gubbins discuss best practices to get the most out of your deals. Brought to you by